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1. Abstract 
Introduction 
A biomarker is a measurable indicator of normal biologic processes, pathogenic processes or 
pharmacological responses. The identification of a useful biomarker is challenging, with 
several hurdles to overcome before clinical adoption. This review gives a general overview of 
a range of biomarkers associated with inflammatory bowel disease or colorectal cancer along 
the gastrointestinal tract. 
Areas covered 
These markers include those that are already clinically accepted, such as inflammatory 
markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins 
(FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal 
microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, 
Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic 
compounds and pH.  
Expert commentary 
There are currently a few biomarkers that have been sufficiently validated for routine clinical 
use at present such as FC. However, many of these biomarkers continue to be limited in 
sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to 
improve diagnosis and monitoring but further study is required to determine efficacy and 
validate clinical utility. 
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3. Introduction 
A biomarker is defined as an objectively measurable characteristic that is objectively 
measured and evaluated as an indicator of normal biologic or pathogenic processes, 
pathogenic processes or pharmacological responses to a specified therapeutic intervention 
[1]–[3]. Ideally it should be measured from easily obtained bodily fluids and waste such as 
plasma, serum, urine and faecal matter for improved patient acceptance; if not feasible then 
invasive techniques such as tissue biopsy are acceptable. An ideal biomarker would be 
sensitive to a specific condition. A useful biomarker has the potential to improve diagnosis, 
discriminate ill patients according to disease, reduce healthcare costs, expedite drug 
development and monitor therapeutic efficacy.  
In this review, a general overview is given of established and potentially new biomarkers found 
within the intestinal lumen, such as proteins, enzymes, microbes and their metabolic products 
(summarised in Table I) are assessed in terms of their usefulness for the diagnosis of 
conditions such as colorectal cancer (CRC) and inflammatory bowel disease (IBD). Combined 
with advances in point of care diagnostics and minimally invasive therapies, these biomarkers 
may be expected to improved patient outcomes in the future.  
 
4. Luminally expressed gastrointestinal biomarkers 
 
4.1. Markers of inflammation 
 
4.1.1. Phagocyte-derived proteins as markers of inflammation 
Markers derived from phagocytes are useful as indicators of inflammation, with those 
expressed only by phagocytes being more specific. Markers which are also inducible in 
epithelial cells are more sensitive, but their levels can be raised by other non-inflammatory but 
still physiologically stressful conditions, such as lactose intolerance. Neutrophil activation 
markers have been found to be involved in the pathogenesis of inflammatory bowel disease 
(IBD), therefore their levels often show good correlation with disease activity. However, 
cytokines such as the interleukins and tumour necrosis factor-alpha (TNFα) tend to be short-
lived and are unstable molecules, and methods for their detection are unreliable [4], [5]. 
Lactoferrin, polymorphonuclear (PMN)-elastase, myeloperoxidase (MPO) and human 
neutrophil lipocalin are markers of neutrophil degranulation, which can be detected in stool, 
and have therefore been proposed as markers of gastrointestinal (GI) tract inflammation. 
Lactoferrin, an iron binding glycoprotein, is considered the most accurate of these, but is also 
found in epithelial cells and consequently has limited specificity. In a large meta-analysis [6], 
lactoferrin was found to have a sensitivity of 82% and specificity of 79% for IBD, compared to 
a sensitivity of 49% and specificity of 92% seen in C-reactive protein (CRP). How lactoferrin 
is involved in inflammatory pathways is not well-established [7]–[9]. PMN-elastase has been 
used to determine the severity of acute pancreatitis, with the advantage of being elevated 
earlier than conventional markers such as CRP. Markers of eosinophil degranulation, mainly 
eosinophilic cationic protein and eosinophilic protein X, have been found to have some use in 
intestinal hypersensitivity and eosinophilic inflammation [4]. 
A major drawback of using phagocyte-derived proteins as markers of inflammation is their lack 
of specificity to the GI tract, as they are expressed during any inflammatory process. For 
example, neutrophil MPO has found use in assessing other inflammatory conditions including 
lung inflammation in smokers [10], [11]. 
4.1.2. Faecal Calprotectin 
 
The S100 proteins are a family of phagocyte-specific damage-associated molecular pattern 
molecules (DAMPs). They encompass a family of over 20 known calcium-binding proteins with 
tissue-specific expression patterns. S100A8, S100A9 and S100A12 are specifically linked to 
innate immune functions by their expression in phagocytes [4]. 
The S100A8/S100A9 complex is better known as faecal calprotectin (FC). FC is a calcium and 
zinc binding heterodimer protein with a regulatory role in the inflammatory process, and is 
released during cell activation and cell death. It constitutes about 60% of soluble proteins in 
human neutrophilic cytosol and is also found in monocytes, macrophages and ileal tissue 
eosinophils. It is excreted into the gut lumen as a response to inflammatory stimuli and is 
therefore six times more concentrated in faeces than in plasma and other bodily fluids [12].  
FC is currently in wide clinical use as a marker of IBD activity, both in screening patients with 
suspected IBD and monitoring disease activity in those with an established diagnosis. In daily 
clinical practice, FC has proven useful due to the ease of collection of stool samples; the 
complex is stable at room temperature, resistant to degradation and homogeneously 
distributed in stool [8], [9], [12]–[14]. The current literature supports the use of FC as a 
screening and monitoring biomarker for both main forms of IBD – ulcerative colitis (UC), 
characterised by mucosal colonic inflammation, and Crohn’s disease (CD), which can affect 
all parts of the gastrointestinal tract with transmural inflammation. The cut-off point for “normal” 
FC is usually taken to be 50 µg/g of stool, as specified by the test manufacturers; however 
cut-off values vary widely depending on clinical situation and even these values are still a 
matter of debate and study. Conventionally, cut-off values of 50-100 µg/g have been reported 
in the literature, depending on individually calculated receiver operative curves in different 
studies. The management of patients with “borderline” FC levels (50-150 µg/g) remains 
unclear as many such patients are not eventually diagnosed with IBD [15]. A summary of the 
various reported FC levels corresponding to different clinical scenarios in IBD is given in Table 
II. 
The use of FC as a screening test in suspected IBD has been shown to reduce the number of 
endoscopies with negative results – in a meta-analysis by van Rheenen et al [6], the pooled 
sensitivity of FC for IBD in adults was 93%, with pooled specificity 96%, and the authors 
estimated that screening with FC would reduce the number of endoscopies required in these 
adults by 67%. Another meta-analysis [16] found that using a cut-off of FC of 50 µg/g gave 
lower sensitivity and specificity (89% and 81%, respectively) compared to FC of 100 µg/g 
(sensitivity 98%, specificity 91%). Gisbert and McNicholl [17] reported that FC had a higher 
diagnostic accuracy for CD (sensitivity 83%, specificity 85%) than UC (sensitivity 72%, 
specificity 74%). Interestingly, these studies and other subsequent ones [18] have found a 
lower specificity of FC for IBD in children of about 70% although sensitivities were comparable.  
FC is also useful in monitoring disease activity in patients with established IBD. Studies have 
shown that FC correlates well with endoscopic disease activity measured using a number of 
different indices including the Rachmilewitz index [19], the modified Baron index in UC [20], 
and Crohn’s Disease Index of Severity (CDIS) [21], [22]. The normalisation of FC has good 
correlation with mucosal healing which is an important prognostic indicator in IBD [23]–[27]. 
By now, several studies have demonstrated that patients with both UC and CD who were in 
remission following medical treatment also had normalisation of FC levels to below 50 µg/g, 
whereas non-responders continued to have elevated FC [28]. Conversely, rising FC 
concentrations in patients with clinically quiescent disease have been found to predict clinical 
relapse with up to 90% sensitivity and 82% specificity. A large meta-analysis by Mosli et al in 
2015 [6] showed overall sensitivity of 88% and specificity 73% for endoscopically active IBD. 
Sensitivities were similar between UC (88%) and CD (87%), but the specificity of FC was lower 
in CD (67%) than UC (79%); this is in line with previous studies [12], [29]. Furthermore, mildly 
elevated levels of FC in unaffected relations of individuals with IBD show its sensitivity to even 
subclinical GI tract inflammation [30], [31]. 
In general, the optimal levels or cut-offs of FC to use vary widely across different clinical 
scenarios and studies. Furthermore, there has been some emerging evidence that FC levels 
may display intra-individual variability from day to day, or even within the same day, observed 
in individuals with active IBD [32], [33], quiescent IBD [34] and also normal individuals [35]. 
Therefore it is suggested that more attention needs to be paid to timing of sample collection 
and the practicalities of sample storage [32], and also that multiple or serial FC measurements 
[33] are obtained. Optimal cut-offs may also differ by disease (UC, CD), brand of assay used, 
distribution of inflammation, and age of patient [36]. Clinical guidance from various 
organisations including the British Society of Gastroenterology [37] and the European Crohn’s 
and Colitis Organisation [38] does not contain a clear-cut definition of “normal” FC and 
recommendations seem to be guided by the trend of an individual patient’s FC levels, i.e. 
increasing or normalising. 
Despite its ease of use and wide adoption, FC is not specific to IBD. Other causes of GI tract 
inflammation can result in elevated FC, including use of non-steroidal anti-inflammatory drugs 
(NSAIDs) [39]–[41] and malignancy [42]–[44]. Another limitation of FC is its inability to localise 
pathology [43], [44]. It is currently thought that FC is more reflective of disease activity in UC 
than in CD, as discussed above, and in colonic CD compared to small bowel CD [31]. 
However, a recent meta-analysis has shown that elevated FC in patients with normal 
ileocolonoscopy was associated with active small bowel inflammation [45]. 
 
4.1.3. S100A12 (Calgranulin C) 
S100A12 (calgranulin C) has recently emerged and may be more specific for IBD than FC. 
Studies have shown that, unlike FC and lactoferrin, it is elevated in IBD but not in conditions 
such as gastroenteritis. This is thought to be because S100A12 is expressed only by 
granulocytes and acts independently of FC in calcium-dependent signalling, hence also being 
thought to be involved in the pathogenesis of IBD [14], [46], [47]. Elevated S100A12 >10 mg/kg 
has been reported to have sensitivity of 96% and specificity of 92% for IBD in children, and 
sensitivity of 86% and specificity of 96% in adults [28]. 
4.1.4. Other markers 
Potential biomarkers are constantly being discovered [48]–[50]. Recent studies on neopterin 
demonstrated its ability to identify patients with IBD with active mucosal lesions and could 
potentially be used to assess the severity their mucosal damage [51].  It was shown that FC 
and neopterin concentrations correlated closer with endoscopic scores for UC (r = 0.75 and r 
= 0.72, respectively; p < 0.0001 for both) than in CD (r = 0.53 and r = 0.47, respectively; p < 
0.0001 for both). Neopterin has a similar overall accuracy to FC in predicting endoscopic 
activity in IBD patients when cut-offs of 250 μg/g for FC and 200 pmol/g for Neopterin were 
used.  
4.2. Fatty acid binding proteins (FABP) 
 
Fatty acid binding proteins (FABPs) are low molecular weight cytosolic proteins found in 
tissues involved in the uptake and consumption of fatty acids. Three forms have been found 
to be expressed by enterocytes: intestinal FABP (I-FABP), liver FABP (L-FABP) and ileal-bile 
acid binding protein (I-BABP). As they are found in the tips of villi, the presence of FABPs in 
the circulation or urine has been considered as a marker of early enterocyte damage [52]. 
I-FABP levels have been shown to increase with acute intestinal ischaemia and inflammation, 
implying correlation with ischaemia-reperfusion injury [52]. For example, a rise in urinary I-
FABP following cardiopulmonary bypass was found to be associated with increased risk of 
postoperative complications [53]. A significant inverse association has also been 
demonstrated between I-FABP and I-BABP and mean arterial pressure, thought to be due to 
intestinal mucosal cell injury secondary to systemic hypotension and consequent hypo-
perfusion [52]. Elevated plasma I-FABP is also associated with poorer outcomes in patients 
with abdominal sepsis [54]. 
The usefulness of these FABPs as GI biomarkers is due to their specificity for gut pathology 
and early elevation following enterocyte damage, allowing a rapid response in time-critical 
conditions such as sepsis. Their excretion in urine is also helpful, especially in the paediatric 
setting. 
 
4.3. Markers of malignancy 
 
4.3.1. Faecal Occult Blood Testing 
Faecal occult blood testing (FOBT) detects traces of blood in stool. The earliest form of FOBT, 
guaiac (gFOBT), is nonspecific for human blood as it is based on the detection of 
pseudoperoxidase activity [55], [56]. Consequently it has relatively low sensitivity and 
specificity; for example, false positives could be obtained due to recent consumption of red 
meat [57]. Therefore, faecal immunochemical tests (FITs), which specifically and quantitatively 
detect human blood through antibody reaction with human globin, are now in wider use. FITs 
are also thought to be more specific for distal GI blood loss such as in CRC. Another form of 
FIT is haemoglobin-haptoglobin (Hb/Hpt) complex testing. Haptoglobin forms a stable soluble 
complex with haemoglobin which is detected via an immunoradiometric assay [58]. A large 
systematic review on the various available forms of FOBT found a wide range of reported 
sensitivities, from 6.2-83.3% for gFOBT and 5.4-62.6% for FITs [59] . Specificity performed 
better, from 65.0-99.0% for gFOBT and 89.4-98.5% for FITs. 
FOBT is widely used worldwide to screen for adenomas and CRC. The use of FOBT has been 
shown to increase early detection of CRC and improve survival [57], [60], [61]. A Cochrane 
review in 2008 [61] concluded that FOBT reduced the relative risk of mortality from CRC by 
16%, with risk reduction increased to 25% when results were adjusted for screening 
attendance. A more recent Cochrane review [62] compared FOBT to flexible sigmoidoscopy 
for the detection of CRC; both modes of screening reduced the relative risk of death from CRC 
(0.72 in flexible sigmoidoscopy vs 0.86 with FOBT). Although flexible sigmoidoscopy 
understandably performed better, FOBT offers advantages as it is cheap and easily 
implemented and therefore suitable for screening large numbers of people efficiently. 
There is little published data on the value of FOBT in predicting small bowel pathology, 
although it is thought to be less useful [63]. 40-60% of subjects with positive FOBT have no 
lesions found in the colon or rectum with colonoscopy, raising the possibility of small bowel 
bleeding [63], [64]. 
4.3.2. Mucins: MUC1, MUC2, MUC5AC, small-intestinal mucin antigen, CDX2, 
villin 
Mucins are high molecular weight glycoproteins expressed in various types of epithelium. 
Specific mucins such as MUC1, MUC2 and MUC5AC have been used as markers for small 
bowel and CRC, as the development and progression of neoplasia are associated with 
aberrant mucin expression [65]–[68]. Similarly, small-intestinal mucin antigen (SIMA) is an 
oncofetal glycoprotein present only in normal small bowel in adults; its abnormal expression 
is associated with adenocarcinomas of the GI tract [65], [69]. Therefore, such markers can be 
useful in distinguishing the types of detected neoplasia in patients and help to guide further 
management. 
Villin is an actin-binding protein involved in brush border maintenance that is specific for 
epithelial neoplasms in the GI tract. It has proven useful in distinguishing between GI tract 
cancer and ovarian, bladder and prostate cancers. Another sensitive marker for GI adenomas 
and especially CRC is CDX2, a homeobox nuclear transcription factor [65]. However there 
remains a dearth of information about the accuracy parameters and therefore utility of these 
markers and they are currently not in routine use. 
4.4. Faecal or Stool DNA (sDNA) 
During the evolution of normal colonocytes into CRC, an accumulation of genetic mutations 
and epigenetic alterations occurs within aberrant colonocytes [70].  These cells are 
continuously exfoliated into the lumen and passed in faeces [71]. 
Genetic variations are represented by various mutations [72] such as KRAS and APC.  
Additional changes are represented by epigenetic aberrant hyper- or hypo-methylation [73].  
Aside from their role in the genesis and propagation of CRC, these modified molecules have 
a demonstrated role as biomarkers.  This is due in part to their presence in plasma/serum [74], 
urine [75] and stool [76].  Furthermore it has been noted that the mutated genetic material 
remains stable in the stool [77] and can be further stabilised ex vivo using buffers [78].  
Amplification and means of detection employ variations of polymerase chain reaction (PCR) 
[79], [80]. 
As a screening modality, sDNA has demonstrated variable sensitivity and specificity with 
performance linked to the markers analysed and in what combination they are analysed.  A 
meta-analysis by Zhai et al [81], including 53 studies, calculated a pooled sensitivity of 48% 
and specificity of 97% for single gene testing.  Multigene testing experienced an improved 
pooled sensitivity of 77.8% with a slightly lower specificity of 92.7%.  The authors speculate 
that the improved multigene sensitivity is due to evaluating sDNA more broadly while 
simultaneously maintaining a precise mutation search.  Compared to FIT, multigene sDNA 
demonstrated superior sensitivity but lower specificity when performed in an asymptomatic, 
average risk individual [82].  In a large cross-sectional study (n = 9,989), Imperiale and 
colleagues compared FIT against multitarget sDNA (MT-sDNA) for aberrant KRAS, NDRG4, 
BMP3 and β-actin for DNA quantity reference.  Post stool analysis, participants underwent 
colonoscopy as the reference standard.  Sensitivity for CRC detection was 92.3% for MT-
sDNA and 73.8% for FIT (p = 0.002).  Detection of advanced precancerous lesions measuring 
> 1 cm, including advanced adenomas and sessile serrated polyps, resulted in sensitivities of 
42.4% and 23.8% for MT-sDNA and FIT, respectively (p < 0.001).  Specificity of sDNA was 
86.6% and 94.9% for FIT (p < 0.001).  Approval by the FDA of MT-sDNA testing was granted 
in August, 2014 [83]. 
In addition to its utility in screening for CRC, sDNA may have a potential role in prognosis and 
as a predictive biomarker [84].  This opinion is echoed by Okugawa et al [17] with particular 
attention directed towards CpG island methylator phenotype (CIMP) as a promising prognostic 
indicator.  This is due to CIMP positive tumours correlating with a negative prognosis as 
indicated by Phipps et al [85].  Furthermore CIMP positive status was employed as a predictor 
of 5-FU response [86] though this has since been refuted [87].  However a meta-analysis by 
Juo et al [88] was inconclusive due to lack of standardisation and recommended further follow-
up with a RCT.     
Comparative-effectiveness studies are now needed to clarify the role of stool DNA testing with 
respect to programmatic screening with other test options. Only through a better 
understanding of other key factors, such as the screening interval, adherence, cost, and 
diagnostic evaluation of positive results, can we determine the appropriate place for stool DNA 
testing on the screening menu [89]. 
4.5. Faecal microRNA (miRNA) 
MicroRNA (miRNA) is a short single stranded string of non-coding RNA [90].  This family is 
18-25 nucleotides in length and plays a role in the regulation of oncogenes and tumour 
suppressors [91].  Altered miRNA expression, in the form of up or down regulation, has been 
linked to a number of cancers including CRC [92], as well as to IBD [93]. The small hairpin 
structure of miRNA renders it resistant to RNAse. It thus demonstrates a high degree of 
stability in a number of media including blood and faeces [94], [95] and can be recovered from 
fixed and frozen tissue [96].  Detection and quantitation is by PCR and microarray analysis 
with other means being investigated [97]. 
Several groups have run pilot studies aimed at investigating miRNA profiles and biomarker 
potentials in human stool samples [95], [98], [99].  Wu at al compared miRNA-21 and -92a 
levels in pre- and post-surgery CRC patients, individuals with polyps and healthy controls 
[100].   It was first noted that stool based miRNA-92a detection was robust and reproducible 
over a 72 hour time span.  Significantly higher miRNA levels were noted in CRC patients than 
in healthy controls (p < 1.01 and p < 0.0001 for miRNA-21 and -92a respectively).  
Furthermore, miRNA-92a was significantly elevated in the patients with polyps group versus 
the healthy controls (p < 0.0001).  Interestingly, tumour removal resulted in a reduction of both 
miRNA-21 and -92a (p < 0.01) and a decrease in miRNA-92a for advanced adenoma excision 
(p < 0.05). Further investigation compared miRNA-135b amongst four different groups, which 
included patients with CRC, adenomas, IBD and healthy controls [100].  The use of an IBD 
group was to restrict markers to individuals with neoplastic disease.  From an array analysis, 
miRNA-31 and 135b were identified as the most unregulated.  MiRNA-135b was found to be 
significantly higher in patients with CRC (p < 0.0001) and adenomas (p < 0.0001) than in the 
IBD and control groups. Furthermore, an increasing trend was noted along the adenoma to 
carcinoma spectrum (p < 0.0001).  Additional results showed that miRNA was indifferent to 
proximal or distal location of the lesion and target stool levels dropped post excision. The 
sensitivity and specificity of miRNA-135b for CRC were 78% and 68%, respectively. Sensitivity 
for adenomas was 65% and further improved to 73% for advanced adenomas. 
Additional evaluation of miRNA and comparison to FIT was done by Koga et al [98].  Tests 
were carried out on confirmed CRC patients and healthy controls.  Sensitivity and specificity 
for miRNA-106a alone were 34.2% and 97.2% respectively versus significant (p = 0.001) FIT 
results of 60.7% and 98.1%, respectively.  However when combined, sensitivity was elevated 
to 70.9% with a slight drop in specificity to 96.3%.  Further investigation by Ahmed et al 
discovered the over and under-expression of a number of miRNA targets [99].  These results 
illustrate the feasibility of miRNA as a non-invasive biomarker for colon-related neoplasia 
screening, due to the feasibility of collecting stool as well as the change in miRNA expression 
levels along the adenoma-carcinoma spectrum, correlating with TNM staging 
4.6. Markers of other pathology 
4.6.1. Faecal Elastase 
Faecal elastase-1 is an enzyme specific to the human pancreas. It is currently used as a test 
for exocrine pancreatic insufficiency as it is not degraded during intestinal transport and is 
therefore testable in a stool sample [101], [102]. Its faecal concentration has been found to 
correlate with levels of pancreatic enzyme secretion but sensitivity and specificity have been 
shown to vary. Faecal elastase performs better in moderate to severe pancreatic insufficiency 
but has been shown to be superior to other tests of pancreatic function [102]–[104]. 
4.6.2. Faecal alpha-1-antitrypsin 
Faecal alpha-1-antitrypsin is a marker of GI plasma loss or protein losing enteropathy, with 
the advantage that it is less invasive than the use of radiolabelled macromolecules. 
Furthermore, it shows good correlation with protein loss and is a relatively inexpensive test 
[5]. It was previously used as a marker of CD but its use has declined with the introduction of 
FC and other more specific markers [105], [106]. 
4.6.3. Alpha2-macroglobulin 
Alpha2-macroglobulin is a protease which has been used as a marker for protein losing 
enteropathy and pancreatitis. It has been suggested that increased protease activity and 
consumption in certain inflammatory conditions such as acute pancreatitis, sepsis and IBD 
could cause its levels to fall [5]. However, it is highly non-specific and there is little conclusive 
evidence to support its routine use. 
4.7. Microbiota 
There are approximately 100 x 1012 microorganisms within the GI tract, an order of magnitude 
greater than the number of somatic cells within the body. These microorganisms primarily 
reside within the large intestine and include bacteria, yeasts, single eukaryotes and more. This 
section will primarily discuss the role of bacteria on GI health. Several factors aid bacterial 
growth within the large intestine, such as the slow transit time of the colon, neutral pH and low 
bile salt concentration [107]. Bacteria are located within two sections of the large intestine 
[107]–[109]. As the colon is devoid of oxygen, most of this bacterial population is anaerobic. 
The bacteria within the large intestine provide several useful functions such as protection of 
epithelial cells, aid the immune system, stimulation of intestinal angiogenesis, and 
fermentation of nondigestible dietary fibre, cellulose, resistant starches, gums and pectins, 
leading to the production of short-chain fatty acids (SCFA) which are an energy source for 
colonocytes [89],[90]. 
Whilst reflective of the community in the colonic lumen, the microbiome in the luminal section 
may not reflect the composition of the epithelial and cryptal community. The microbiome in the 
mucosa is a dense community of bacteria that adheres to the surface. That can withstand the 
hydrodynamic shear forces present [111]. Adherent resident bacteria may play a role in the 
development of IBD and CRC.  
The Human Microbiome Project and other research show that there is a high degree of 
variation in the bacterial populations between individuals [2] [112] and studies have shown 
that factors such as age, diet, ethnicity and environment may contribute to this variation. 
Despite the dissimilarities, many of these bacteria that carry out common metabolic activities 
are similar between different individuals [113]. Commonly found genera of bacteria within the 
adult large intestine include Bifidobacterium, Eubacterium, Lactobacillus, Bacteroides, 
Clostridium, Escherichia, Streptococcus and Ruminococcus. Bacteroides is one of the most 
abundant within the GI tract, with Eubacterium, Bifidobacterium, Peptostreptococcus, and 
Ruminococcus also widespread [107],[114].  
An increasing number of studies have demonstrated that there is a relationship between 
changes in the gut microbial population and the development of diseases such as IBD [96]–
[101] and CRC [107], [110], [111], [122]–[137]. A summary of some of these studies is shown 
in Table III.  Many of the trials shown in this table use a relatively small number of samples, 
which limits the wider applicability of the results. Additionally, several studies have identified 
changes in different bacterial populations to be linked to the same GI disease. One 
contributing factor may be that many of the studies shown in Table III were conducted using 
stool samples as a proxy for mucosal samples due to ease of collection. However it is unknown 
to what extent the faecal and mucosal microbiomes differ, which may have influenced the 
results of these studies [138]. Besides the use of faecal biota as opposed to mucosal biota, 
other factors that may limit the widespread applicability of these studies may include lack of 
information regarding microbiota patchiness, and heterogeneity between different anatomical 
niches along the colon, difference due to ages and genders, and other factors, limit the 
usefulness and [2]. 
It is unclear, whether the changes in gut microbiota contribute to disease pathogenesis or 
whether they occur due to local inflammation [139]. The bacterial driver-passenger model 
proposed by Tjalsma could explain the influence of microbiota on the development of GI 
disease [140]. This model suggests that certain populations of driver bacteria with pro-
carcinogenic features damage intestinal epithelium DNA, leading to tumorigenesis, which in 
turn alters the intestinal environment leading to a decline in homeostasis due to overgrowth of 
opportunistic passenger bacteria.  
Study of the gut microbiome is still in its infancy and the lack of a holistic understanding of this 
complex environment and its role in gut pathology presents a major barrier to the identification 
of bacteria or combinations of bacteria as potentially reliable, specific and sensitive biomarkers 
for CRC and IBD. Currently, identification of the microbial constituents can be performed 
through use of molecular fingerprinting methods and sequence analysis of cloned microbial 
ribosomal DNA due to difficulties in cultivation.  These methods are expensive and take time, 
which currently impedes the recognition of widely accepted biomarkers for clinical usage. The 
development of inexpensive, minimally invasive, rapid and reliable technologies for direct 
sampling and analysis of the microbiome will aid the design and operation of clinical trials 
necessary in identifying these biomarkers and utilising them to aid diagnosis in future. 
4.8. Volatile Organic Compounds 
Direct intra-luminal measurement of microbiota population and demographics may not be 
possible with current technology. However, the competition between different populations of 
bacteria for resources such as substrates or hydrogen can lead to deviations in the 
concentrations of metabolic by-products such acetic, propionic and butyric acids, CO2, H2, 
CH4, NH3, H2S and volatile fatty acids [141]. These changes in metabolic activity may be 
reflected in changes in the constituent gases of the patients of breath. Diagnosis by breath 
analysis is an area of much interest as measurements are non-invasive and potentially near 
real time, making it ideal for screening or point of care diagnosis. However, this is not trivial 
as human breath is a complex mixture of gases containing at least 3000 different compounds 
[142], which includes more than 800 volatile organic compounds (VOCs). Changes in the 
relative concentration of the VOCs may correlate with pathological or physiological changes 
[143]. 
Several studies have proposed various VOC biomarkers for CRC or IBD [144]–[157] with the 
results of some of these studies shown in Table IV. However, the sample size for these 
studies has been small, which may be a factor in different biomarkers being identified for the 
same pathologies. Further study is needed amongst a larger population to identify useful, 
widely applicable biomarkers for the detection of GI disease. 
The rapid development and expansion of capsule endoscopy functionality through increased 
use of microengineering has enabled integration of various sensing modalities, such as gas 
sensors into these diagnostic tools [158], [159]. While, the prospect of direct or indirect 
sampling and subsequent analysis of the VOCs produced within the GI tract for clinical 
diagnosis is attractive, there is a need for further large, randomised and blinded studies before 
reliable, sensitive and specific VOC markers can be definitively identified for the diagnosis of 
GI pathology in clinical applications. 
 
4.9. pH 
Changes in luminal pH along the GI tract is an established subject of interest. The pH values 
of a typical, healthy GI tract is generally agreed to be as shown in Table V, showing an 
increase from the duodenum to the terminal ileum, a decrease in the caecum and a slow rise 
along the colon to the rectum. The values can change based on time since time since 
ingestion, diet, age and other factors [160],[161]. Changing pH along the GI tract occurs for 
several reasons, such as the absorption of acetate, propionate, butyrate and other short chain 
fatty acids, fermentation, and production of alkaline metabolites [114].   
It has been proposed that UC  and to some extent other IBDs such as CD can cause a 
decrease in pH due to mucosal inflammation within the colon [158]-[160], but this is subject to 
debate [162]. Drawing conclusions is difficult due to the small size of the studies, variations in 
dietary intake, extent and severity of the colitis, and possible signal loss or drift due to the use 
of endoscopic capsules. Several studies have shown that CRC is not linked with any 
significant change in pH [163]–[165] despite an earlier hypothesis [166] that acidification of 
the bowel may play a role in the aetiology of CRC.  
5. Expert Commentary 
Endoluminal biomarkers such as FC and lactoferrin have changed the management of GI 
disease, allowing detection at an earlier stage or improved diagnostic certainty. The increased 
understanding of GI disease pathogenesis and progression due to the emergence of omics in 
recent years has led to the identification of thousands of potential biomarkers. However, there 
remain significant limitations to their use. These limitations include the low sensitivity and/or 
specificity of tests like FOBT and current lack of comprehensive understanding of the 
complexities of the gut microbiome. Other barriers to clinical adoption include clinician 
education in the conduct and interpretation of tests, and the relevant costs. Therefore, only a 
few biomarkers have been sufficiently validated for routine clinical use at present. 
Nevertheless, emerging biomarkers have the potential to improve clinical practice, for example 
accurate VOC biomarkers could improve the rate of screening of CRC in the wider population 
due to the non-invasive and rapid nature of breath analysis, various stool biomarkers could 
offer non-invasive testing with quicker results than serum markers. The study of these 
biomarkers and development of testing methods could also further increase understanding of 
GI disease mechanisms and therefore improve management, patient care and outcomes. 
 
6. Five Year View 
The transfer of biomarkers from benchtop to clinical practice is not trivial. To become clinically 
approved, an effective biomarker must be validated using hundreds of samples, be specific -  
able to correctly identify a high proportion of true negative rates; sensitive - able to correctly 
identify a high proportion of true positives and also be reproducible - able to achieve the same 
level of detection under similar conditions multiple times. Validation of biomarkers in 
independent cohorts from several different institutions will help this process. To date, no 
marker has been found with 100% sensitivity and specificity for any GI disease. However, 
several solutions have been proposed to help biomarkers progress from the initial preclinical 
exploratory stage to final control studies. These include improving the assay used for 
detection, effective use of biomarker combinations and identification of the subpopulations in 
which the biomarker is most effective for use as a stratified diagnostic tool. This will be helpful 
for verifying potential VOC and microbiota biomarkers that have so far been identified in small 
studies, prone to bias due to various factors such as diet, ethnicity and age. Over the next five 
years, the increasing adoption of inexpensive, point of care diagnostic tools in labs will enable 
quicker screening and characterisation of effective biomarkers or combinations of biomarkers 
for various GI diseases, thereby speeding up the route to clinical adoption.  
 
7. Key Issues 
• There are currently well-established biomarkers such as FC. However, biomarkers 
continue to be limited in sensitivity and specificity for various GI diseases. 
• Several biomarkers show potential but further study is needed to determine their 
efficacy, validate their use and overcome barriers to clinical adoption. 
• New and emerging GI biomarkers could improve disease diagnosis and monitoring 
through better sensitivity, specificity and/or ease and speed of measurement. 
• A greater understanding of the role of the microbiome in GI disease is important for 
future biomarker identification and more effective use of existing but not yet well-
established biomarkers. 
• The ideal biomarker is easy to obtain from patients (e.g. stool, urine or breath 
samples as opposed to serum) and has an inexpensive test, which is easy to conduct 
and interpret, with excellent sensitivity and specificity. 
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 Table I: Summary of biomarkers 
Type Biomarker Possible Cause Advantages Disadvantages References 
 
 
 
 
 
 
 
 
Inflammation 
markers 
Phagocyte 
derived protein 
Inflammatory 
bowel disease 
Good sensitivity to IBD.  Lack of specificity to 
inflammation of the 
GI tract 
[5], [8]–[10], 
[167], [168][6] 
Faecal 
Calprotectin 
Inflammation Well established, relatively 
inexpensive 
Moderate specificity 
for IBD 
[8], [11]–
[15],[17]–[29][6] 
[15] [16] [17] [18] 
[19], [20], [21], 
[22]. [23]–
[27].[28] 
S100A12 
(Calgranulin 
C) 
Inflammatory 
bowel disease 
Initial studies show greater 
specificity than faecal 
calprotectin for IBDA 
Larger studies 
required 
[14], [46], [47] 
Fatty acid 
binding 
proteins 
Inflammation 
associated with 
early stage 
enterocyte 
damage 
Good specificity for gut 
pathology 
Useful for time critical 
conditions such as sepsis 
due to early elevation 
following enterocyte 
damage 
Excretion of urine useful for 
sample collection 
Larger studies 
required 
[52]–[54] 
 
 
Malignancy  
markers 
Faecal Occult 
Blood Testing 
Distal GI blood 
loss 
Popular and inexpensive 
method of screening 
Low sensitivity and 
specificity 
Little published 
work on its value as 
a predictive marker 
[33]–[37], [38], 
[39], [58] [59] [61] 
[62] 
Mucins Small bowel and 
colorectal 
adenocarcinomas 
 Lack of 
comprehensive 
information 
regarding accuracy 
and utility of mucins 
as a biomarker 
[65]–[69] 
 
Faecal DNA 
KRAS 
 
 
Colorectal cancer 
Initial studies show 
moderate sensitivity and 
good specificity.  
Trend in reduction in cost of 
analytical equipment.   
Larger studies 
required.  
[45]–[55], [56], 
[57], [59]–[63] 
APC 
CIMP 
 
Faecal 
microRNA 
miRNA-21 
 
 
 
Colorectal cancer 
Initial studies show good 
sensitivity and specificity  
Trend towards reduction in 
cost of analytical equipment 
Larger studies 
required 
[90]–[99] [100].    
miRNA-92a 
miRNA-106a 
miRNA-135b 
 
 
 
 
 
 
Enzymes 
Faecal 
Elastase-1 
Pancreatic 
function 
Good correlation with 
pancreatic enzyme 
secretion 
Demonstrated superior 
performance to other tests 
of pancreatic function.  
Varied sensitivity 
and specificity.  
Limited to moderate 
and severe 
pancreatic 
insufficiency 
[101]–[104] 
Faecal alpha-
1-antitrypsin 
GI plasma loss or 
protein losing 
enteropathy 
Good correlation with 
protein loss.  
Relatively inexpensive to 
perform 
Less specific than 
faecal calprotectin 
and other markers 
that have 
superceded it in 
terms of usage 
[105], [106][5] 
Alpha2-
macroglobulin 
Protein losing 
enteropathy and 
pancreatic, sepsis 
and inflammatory 
bowel disase 
Good correlation with acute 
pancreatitis, sepsis and IBD 
Non specific 
Little conclusive 
evidence to support 
routine use 
[5][171] 
 
 
 
 
 
Other 
Microbiota Colorectal cancer, 
inflammatory 
bowel disease 
See Table III for further 
information 
Knowledge of the 
role of microbiota 
on GI pathology 
still in its infancy 
Further studies 
required to identify 
reliable microbiota 
biomarkers 
See Table III for 
further information 
[107], [110], 
[111], [122]–
[127], [129]–
[137], [139], 
[171]–[177] 
Volatile 
Organic 
Compounds 
 Potential for minimally 
invasive detection of GI 
disease without need to 
handle stool or urine 
samples.  
See Table IV for further 
information 
Knowledge of the 
volatilome still 
basic, requiring 
further studies to 
link changes in gas 
concentration to 
pathology.  
More accurate and 
inexpensive 
methods of gas 
detection also 
required.  
See Table IV for 
further information 
[144]–[157] 
pH Inflammatory 
bowel disease 
 Further study 
required due to 
confounding factors 
such as age, diet 
and other factors.  
[162]–[166], 
[178]–[180] 
 
 
 Table II: Summary of use of faecal calprotectin in IBD 
Clinical scenario FC levels 
Diagnosis >50 usually used to distinguish between IBD and functional 
disorders; however 50-150 is generally considered a grey area 
>100 has better specificity but sensitivity varies between studies; is 
considered “strongly positive” 
Active vs inactive 
IBD 
>100: endoscopically active CD 
>250: large ulcers seen on endoscopy 
<250: mucosal healing on endoscopy/ endoscopic remission 
In general, normalisation of FC correlates with mucosal healing. 
Treatment response Rise in FC >100 predicts clinical relapse 
Normalisation of FC or at least <75% reduction from baseline can 
be used as surrogate marker for mucosal healing 
Normalisation of FC to below 100 may predict clinical remission 
Postoperative 
recurrence in CD 
>100-200 (depending on study) 
In general, a rise in FC is considered significant 
FC expected to normalise within 2 months after uncomplicated 
ileocaecal resection; persistently raised FC could reflect ongoing 
inflammation 
Relapse >250 measured 3 months after diagnosis: high relapse risk in UC 
>500: thought to distinguish high relapse risk from low relapse risk 
(paediatric study) 
 
Table III: Summary of experiments demonstrating relationship between changes in microbiome and presence of disease 
Disease Bacteria Sample Subjects Clinical Outcome Reference 
Crohn’s Disease Faecalibacterium prausnitzzi, 
Escherichia coli 
Biopsy 
samples 
DNA analysis of biopsy collected from 5 
locations between ileum and rectum from 6 
discordant monozygotic twin pairs against 
4 concordant pairs 
Patients with ileal Crohn’s disease had a 
reduced population of Faecalibacterium 
prausnitzzi (p<0.001) and an abundance of 
Escherichia coli (p<0.03) compared to 
healthy concordant twins and those with 
colon localised Crohn’s 
[172] 
Crohn’s Disease Escherichia coli Biopsy 
samples 
28 patients were studied: 13 with Crohn’s 
disease involving the ileum, 8 with Crohn’s 
Ileal mucosa found to have a population of 
Escherichia coli (P<0.001), but relatively 
depleted in a subset of Clostridiales (P<0.05) 
[181] 
disease restricted to the colon but with a a 
normal ileum versus 7 healthy patients  
and negative for  Mycobacterium avium 
subspecies paratuberculosis, Shigella and 
Listeria. The population of Escherichia coli 
was found to positively correlate with severity 
of Crohn’s disease (P<0.001).  
Inflammatory Bowel 
Disease 
Butyricicoccus pullicaecorum Stool 
samples 
51 patients with Crohn’s disease, 25 with 
Ulcerative Colitis versus 88 healthy 
controls 
The average number of Butyricicoccus 
bacteria was significantly (p<0.0001) lower in 
the stools of IBD group versus healthy 
controls. A significantly lower level of 
Butyricicoccus species was observed in the 
faecal microbiota of patients with active CD 
compared with CD in remission (p<0.0188) 
[173] 
Inflammatory Bowel 
Disease 
Bdellovibrio bacteriovorus Biopsy 
samples 
9 patients with Crohn’s, 6 patients with 
Ulcerative Colitis versus 8 healthy controls 
Statistically higher population of B. 
bacteriovorus in ileum, colon, and rectum of 
control biopsies with respect to CD 
(p<0.0001). No difference was found among 
overall UC and control samples p=0.6760). 
[171] 
Ulcerative Colitis Faecalibacterium prausnitzii 
Roseburia hominis 
Stool 
samples 
127 patients with Ulcerative Colitis (39 
active, 88 in remission) versus 87 healthy 
controls 
Real-time PCR analysis revealed a lower 
abundance of Roseburia hominis (p<0.0001) 
and Faecalibacterium prausnitzii (p<0.0001) 
in UC patients compared to controls 
[174] 
Colorectal cancer Roseburia 
Microbacterium 
Anoxybacilus 
Biopsy 
samples 
8 patients  (4 with colon cancer and 4 with 
rectal cancer). Study was performed with 
16 tissue samples taken during 
colonoscopy, 8 taken from healthy tissue 
and 8 taken from cancerous tissue.  
50% of Chinese CRC patients, we found a 
significant increase of Roseburia (p = 0.017), 
and a concurrent decrease of both 
Microbacterium (p = 0.009) and 
Anoxybacillus (p = 0.009) in tumor tissue 
[175] 
Colorectal cancer Fusobacteria 
Eubacteriaceae 
Clostridiales Family XI. 
Incertae sedis 
Staphylococcaceae 
Bacteroides 
Campylobacteraceae 
Porphyromonadaceae 
Enterococcaceae 
Stool 
samples 
19 patients with CRC versus healthy 
controls 
Increased population of Fusobacteria 
(p<0.01), Eubacteriaceae (p=0.037), 
Clostridiales Family XI. Incertae sedis (p = 
0.004), Staphylococcaceae (p=0.011), 
Bacteroides (p=0.046) compared to healthy 
control group. Reduced population of 
Campylobacteraceae (p=0.014) and 
Porphyromonadaceae (p=0.001) families 
compared to healthy control group. No 
significant change in Enterococcaceae 
(p=0.062). 
[127] 
Colorectal cancer Bacteroides/Prevotella Stool 
samples 
Stool samples taken from 60 patients with 
confirmed colorectal cancer after 
colonoscopy versus healthy controls 
Elevated population of 
Bacteroides/Prevotella in CRC patients 
compared to healthy controls (p = 0.009) 
[124] 
Colorectal cancer Bacteroides 
Roseburia 
Alistipes 
Eubacterium 
Parasutterella 
Porphyromonas 
Escherichia/Shigella 
Enterococcus 
Streptococcus 
Peptostreptococcus 
Stool 
samples 
46 patients with CRC versus healthy 
controls  
Elevated populations of Bacteroides 
(p=0.005), Roseburia (p=0.003), Alistipes 
(p=0.039), Eubacterium (p=0.028), 
Parasutterella (p=0.032) and reduced 
populations of Porphyromonas (p=0.02), 
Escherichia/Shigella (p<0.01), Enterococcus 
(p<0.01), Streptococcus (p=0.018), 
Peptostreptococcus (p<0.01) compared to 
healthy controls 
[176] 
Colorectal cancer Atopobium 
Clostridia 
Fusobacterium 
Porphyromonas 
Stool 
samples 
47 patients with colorectal cancer versus 
healthy controls 
Elevated populations of Bacteroidetes 
observed and a reduced population fo 
Firmicutes (p=0.05) and overall microbial 
diversity was reduced compared to healthy 
controls (p=0.002). Genera such as 
Clostridia were reduced in numbers 
(p=0.005), while increased numbers of 
Fusobacterium (p=0.004), Atipobium 
(p<0.001) and Porphyromonas (p=0.05) 
observed, when compared to healthy 
controls. 
[136] 
Colorectal cancer Acidaminobacter 
Phascolaractobacterium 
Citrobacter farmer 
Akkermanasia mucinphillia 
Bacteroides finegoldii 
Bacteroides intestinalis 
Bacteroides capillosis 
Prevotella copri 
Prevotella oris 
Ruminococcus abeum 
Stool 
samples 
CRC group had decreased overall 
microbial community diversity (p = .02). 
Taxonomical analysis showed reduced 
relative population of Clostridia (p=0.005), 
increased Fusobacterium (p=0.004), 
Atopobium (p<0.001) and Porphyromonas 
(p=0.001) compared to control group.  
Elevated populations of Acidaminobacter 
(p=0.0045), Phascolarctobacterium (p=0.00), 
Citrobacter farmer (p=0.0050), 
Akkermanasia mucinphilia (p=0.0032), 
compared to healthy controls. Elevated 
populations of Bacteroides finegoldii 
(p=0.0032), Bacteroides intestinalis 
(p=0.0063), Prevotella copri (p=0.00), 
Bacteroides capillosis (p=0.0057), Prevotella 
oris (p=0.001), Ruminococcus abeum 
(p=0009), amongst many others in healthy 
controls compared in to CRC group.   
[133] 
 
 
 
Table IV: Summary of experiments demonstrating relationship between presence of disease and specific volatile organic compounds on breath 
Disease Volatile Organic Compounds Method of 
Analysis 
Subjects Clinical Outcome Reference 
Colorectal cancer Methane - 45 patients with colorectal 
cancer versus healthy 
controls 
No significant difference between 
colorectal cancer and control 
groups 
[144] 
Colorectal cancer Methane - 59 patients with unresected 
colorectal cancer versus 
healthy controls 
No significant difference between 
colorectal cancer and control 
groups 
[145] 
Colorectal cancer Methane GC 55 patients with unresected 
colorectal cancer versus 
healthy controls 
No significant difference observed 
between patients with colorectal 
cancer and healthy controls 
[146] 
Colorectal cancer Methane GC 47 patients with unresected 
colorectal cancer, 36 patients 
with resected colorectal 
cancer, 7 with nonresectable 
cancer, 29 with non-
malignant diseases of colon  
The majority of patients (91.4%) 
with unresected colorectal cancer 
produced more methane than 
healthy controls (p<0.001) and 
patients with benign diseases of the 
colon (p<0.001) 
[147] 
Colorectal cancer Ethanol,  
Acetone,  
Ethyl acetate,  
4-methyl octane 
GC-MS 65 patients with colorectal 
cancer, 22 with adenoma 
versus health controls 
Increased Acetone and Ethyl actete 
in CRC patients (p = 0.010, p = 
0.005 respectively) versus healthy 
controls. Reduced Ethanol and 4-
methyl octane in CRC patients  
(p<0.001, p=0.004 repectively) 
versus healthy controls.  
[148] 
Colorectal cancer Non-anal  
4-Methyl-2-pentanone  
Decanal  
2-Methylbutane  
1,2-Pentadiene  
2-Methylpentane  
3-Methylpentane  
Methylcyclopentane Cyclohexane  
Methylcyclohexane  
1,3-Dimethylbenzene  
4-Methyloctane  
1,4-Dimethylbenzene  
4-methylundecane trimethyldecane 
GC-MS 37 patients with colorectal 
cancer versus controls 
Elevated concentrations detected in 
CRC patients compared to control 
[149] 
Colorectal cancer 1,10-(1-butenylidene)bis benzene 
1,3-dimethyl benzene 
1-iodo nonane 
[(1,1-dimethylethyl)thio] acetic acid 
4-(4-propylcyclohexyl)-40-cyano[1,10-biphenyl]-4-yl 
ester benzoic acid 
2-amino-5-isopropyl-8-methyl-1-azulenecarbonitrile 
GC-MS 26 patients with colorectal 
cancer versus controls 
Elevated concentrations detected in 
CRC patients compared to controls 
[150] 
Inflammatory 
Bowel Disease 
Pentane GC 33 inflammatory bowel 
disease patients 
Correlation with disease activity [151] 
Inflammatory 
bowel diseaseiii 
1-Octene, 
1-Nonene,  
1-Decene,  
z3- Methylhexane,  
(E)-2-Nonene,  
Hydrogen sulphide 
SIFT-MS 62 patients with inflammatory 
bowel disease versus 
controls 
Elevated readings of 1-octene, 1-
decene, 3-methylhexane and 
reduced readings of 1-Nonene, (E)-
2-Nonene, hydrogen sulphide in 
IBD patients compared to control. 
P<0.001 
[152] 
Inflammatory 
Bowel Disease 
2-propanol,  
acrylonitrile,  
carbon disulfide,  
dimethylsulfide,  
ethanol,  
isoprene,  
triethylamine 
SIFT-MS 24 patients with Crohn’s 
disease and 11 patients with 
Ulcerative Colitis versus 
healthy controls 
Changes in concentrations of 
gases observed compared to 
healthy controls (p<0.001 for all 
gases). There was no significant 
difference in any VOC levels 
between CD and UC 
[153] 
Irritable Bowel 
Syndrome 
Hydrogen Sulphide MS 27 patients with diarrhoea 
predominant IBS versus 
healthy controls  
Patients confirmed to have small 
bowel intestinal overgrowth (SIBO) 
in irritable bowel syndrome showed 
higher concentrations of H2S 
compared to those that were 
negative SIBO (p<0.001) 
[154] 
Ulcerative colitis Ethane,  
Pentane 
GC 17 active ulcerative colitis 
patients versus controls 
Significantly higher compared to 
controls (p<0.013). Positive 
correlation of ethane with 
endoscopic score, symptom score, 
disease activity and 
chemiluminescence in rectal tissue. 
Pentane levels did not correlate 
with any of the clinical 
measurements 
 
[155] 
Ulcerative colitis 
and Crohn’s 
disease 
Ethane,  
Propane,  
Butane,  
Isoprene 
GC 10 patients with UC and 10 
patients with CD versus HC 
Significant difference between 
elevated patients with IBD and 
controls were found for ethane, 
propane, and pentane (p ranges 
between <0.05 to <0.001), but no 
[156] 
significance found for butane and 
isoprene.  
Ulcerative Colitis,  
Colorectal cancer, 
Crohn’s disease 
Methane GC 20 patients with unresected 
colorectal cancer, 40 patients 
with ulcerative colitis and 40 
patients with Crohn’s disease 
versus healthy controls 
Decreased methane concentration 
on breath of UC and CD patients 
versus healthy controls (p<0.001, 
p<0.001). Increased methane 
concentration on breath of CC 
patients versus healthy controls 
(p<0.005) 
[157] 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table V: Typical pH along GI tract 
Organ pH 
Stomach 2 
Small Intestine 7 
Caecum 6 
Colon 6.5 
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